{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:04Z","timestamp":1790797084817,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10072-021-05426-5","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T13:02:44Z","timestamp":1625490164000},"page":"1273-1280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache"],"prefix":"10.1007","volume":"43","author":[{"given":"Umberto","family":"Pensato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Michela","family":"Cainazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Querzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pascazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mascarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Asioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cortelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pierangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-4295","authenticated-orcid":false,"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"5426_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"JL Natoli","year":"2010","unstructured":"Natoli JL, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599\u2013609","journal-title":"Cephalalgia"},{"key":"5426_CR2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/head.12408","volume":"54","author":"SB Munksgaard","year":"2014","unstructured":"Munksgaard SB, Jensen RH (2014) Medication overuse headache. Headache 54:1251\u20131257","journal-title":"Headache"},{"key":"5426_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lanteri-Minet","year":"2011","unstructured":"Lanteri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837\u2013850","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"5426_CR4","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1007\/s10072-008-0888-3","volume":"29","author":"D D\u2019Amico","year":"2008","unstructured":"D\u2019Amico D, Leone M, Grazzi L, Bussone G (2008) When should \u201cchronic migraine\u201d patients be considered \u201crefractory\u201d to pharmacological prophylaxis? Neurol Sci 29(Suppl 1):S55\u2013S58","journal-title":"Neurol Sci"},{"key":"5426_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1526-4610.2008.01135.x","volume":"48","author":"EA Schulman","year":"2008","unstructured":"Schulman EA, Brahin EJ (2008) Refractory headache: historical perspective, need, and purposes for an operational definition. Headache 48:770\u2013777","journal-title":"Headache"},{"key":"5426_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1526-4610.2008.01132.x","volume":"48","author":"EA Schulman","year":"2008","unstructured":"Schulman EA, Lake AE 3rd, Goadsby PJ et al (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache 48:778\u2013782","journal-title":"Headache"},{"key":"5426_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21:76","journal-title":"J Headache Pain"},{"key":"5426_CR8","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211"},{"key":"5426_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11916-019-0768-y","volume":"23","author":"I Urits","year":"2019","unstructured":"Urits I, Jones MR, Gress K et al (2019) CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr Pain Headache Rep 23:29","journal-title":"Curr Pain Headache Rep"},{"key":"5426_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434","journal-title":"Lancet Neurol"},{"key":"5426_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"5426_CR12","doi-asserted-by":"publisher","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363\u2013372. https:\/\/doi.org\/10.1111\/head.14032","DOI":"10.1111\/head.14032"},{"key":"5426_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10072-019-03769-8","volume":"40","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ (2019) CGRP and headache: a brief review. Neurol Sci 40:99\u2013105","journal-title":"Neurol Sci"},{"key":"5426_CR14","doi-asserted-by":"publisher","unstructured":"Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM, Merli E, Calabr\u00f2 C, Cortelli P, Pierangeli G, Cevoli S (2020) Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna headache center. Neurol Sci 41(2):483\u2013484. https:\/\/doi.org\/10.1007\/s10072-020-04667-0","DOI":"10.1007\/s10072-020-04667-0"},{"key":"5426_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61","journal-title":"J Headache Pain"},{"key":"5426_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32","journal-title":"J Headache Pain"},{"key":"5426_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10072-020-04690-1","volume":"41","author":"M Curone","year":"2020","unstructured":"Curone M, Tullo V, Bussone G (2020) Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache: a prospective observational study. Neurol Sci 41:509\u2013510","journal-title":"Neurol Sci"},{"key":"5426_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21:84","journal-title":"J Headache Pain"},{"key":"5426_CR19","doi-asserted-by":"publisher","unstructured":"Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S (2021) Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-021-05105-5","DOI":"10.1007\/s10072-021-05105-5"},{"key":"5426_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3988\/jcn.2008.4.4.158","volume":"4","author":"HE Shin","year":"2008","unstructured":"Shin HE, Park JW, Kim YI, Lee KS (2008) Headache Impact Test-6 (HIT-6) scores for migraine patients: Their relation to disability as measured from a headache diary. J Clin Neurol 4:158\u2013163","journal-title":"J Clin Neurol"},{"key":"5426_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","volume":"26","author":"P Sarchielli","year":"2006","unstructured":"Sarchielli P, Pini LA, Zanchin G et al (2006) Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 26:257\u2013265","journal-title":"Cephalalgia"},{"key":"5426_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M et al (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 19:91","journal-title":"J Headache Pain"},{"key":"5426_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello R, Tiseo C, Frattale I et al (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99","journal-title":"J Headache Pain"},{"key":"5426_CR24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037","journal-title":"Cephalalgia"},{"key":"5426_CR25","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287","journal-title":"Lancet"},{"key":"5426_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J et al (2020) Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417","journal-title":"Front Neurol"},{"key":"5426_CR27","doi-asserted-by":"publisher","unstructured":"Pensato U, Favoni V, Pascazio A, Benini M, Asioli GM, Merli E, Calabr\u00f2 C, Cortelli P, Pierangeli G, Cevoli S (2020) Erenumab efficacy in highly resistant chronic migraine: a real-life study. Neurol Sci 41(2):457\u2013459. https:\/\/doi.org\/10.1007\/s10072-020-04658-1","DOI":"10.1007\/s10072-020-04658-1"},{"key":"5426_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21:69","journal-title":"J Headache Pain"},{"key":"5426_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/head.13843","volume":"60","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, Do TP, Ashina H, Ashina M, Burstein R (2020) Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache 60:1056\u20131065","journal-title":"Headache"},{"key":"5426_CR30","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:e2309\u2013e2320","journal-title":"Neurology"},{"key":"5426_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6","journal-title":"J Headache Pain"},{"key":"5426_CR32","doi-asserted-by":"publisher","unstructured":"Lipton RB, Burstein R, Buse DC, Dodick DW, Koukakis R, Klatt J, Cheng S, Chou DE (2021) Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. Cephalalgia 3331024211010305. https:\/\/doi.org\/10.1177\/03331024211010305","DOI":"10.1177\/03331024211010305"},{"key":"5426_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1468-2982.2006.01255.x","volume":"27","author":"A Ashkenazi","year":"2007","unstructured":"Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB (2007) Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 27:111\u2013117","journal-title":"Cephalalgia"},{"key":"5426_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10072-018-3661-2","volume":"40","author":"JG Seo","year":"2019","unstructured":"Seo JG, Park SP (2019) Clinical significance of sensory hypersensitivities in migraine patients: does allodynia have a priority on it? Neurol Sci 40:393\u2013398","journal-title":"Neurol Sci"},{"key":"5426_CR35","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14737175.2016.1208565","volume":"16","author":"C Lovati","year":"2016","unstructured":"Lovati C, Giani L, Mele F et al (2016) Brain plasticity and migraine transformation: fMRI evidences. Expert Rev Neurother 16:1413\u20131425","journal-title":"Expert Rev Neurother"},{"key":"5426_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","volume":"40","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci 40:177\u2013179","journal-title":"Neurol Sci"},{"key":"5426_CR37","first-page":"1052","volume":"24","author":"TJ Schwedt","year":"2018","unstructured":"Schwedt TJ (2018) Preventive therapy of migraine Continuum (Minneap Minn) 24:1052\u20131065","journal-title":"Preventive therapy of migraine Continuum (Minneap Minn)"},{"key":"5426_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K et al (2017) Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 18:96","journal-title":"J Headache Pain"},{"key":"5426_CR39","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2019) Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39:1455\u20131464","journal-title":"Cephalalgia"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05426-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T07:05:48Z","timestamp":1643439948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05426-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5426"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05426-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by an independent ethics committee or local institutional review board at each participating site, and written informed consent was obtained from all enrolled patients. All clinical investigations were conducted according to the latest version of the Declarations of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was collected from the patients for the inclusion of deidentified clinical data in a scientific publication, in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors agreed with this final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Carlo Baraldi and Simona Guerzoni received travel grants and honorary from Allergen, Novartis, Teva, and Ely Lilly. Maria Michela Cainazzo received travel grants and honorary from Allergen, Novartis, IBSA, and Ely Lilly. Sabina Cevoli received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, and Lundbeck. Valentina Favoni received honoraria as a speaker or for participating in advisory boards from Ely-Lilly, Novartis, and Teva. The other authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}